Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $18.00.

CADL has been the topic of several research analyst reports. Citigroup decreased their price target on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, January 21st. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Stephens reissued an “overweight” rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday, December 8th.

Candel Therapeutics Price Performance

CADL stock opened at $5.17 on Wednesday. Candel Therapeutics has a one year low of $4.25 and a one year high of $9.08. The company’s fifty day moving average price is $5.58 and its 200-day moving average price is $5.41. The company has a debt-to-equity ratio of 0.91, a quick ratio of 13.49 and a current ratio of 13.49. The company has a market capitalization of $283.83 million, a PE ratio of -7.28 and a beta of -0.91.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, March 12th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.30). On average, equities analysts anticipate that Candel Therapeutics will post -1.47 EPS for the current fiscal year.

Insider Activity

In other news, Director Paul B. Manning bought 550,458 shares of the stock in a transaction dated Monday, February 23rd. The stock was purchased at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the transaction, the director owned 2,763,527 shares of the company’s stock, valued at $15,061,222.15. The trade was a 24.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 16.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Candel Therapeutics during the fourth quarter valued at $51,000. Tower Research Capital LLC TRC lifted its position in Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares during the last quarter. Invesco Ltd. purchased a new position in shares of Candel Therapeutics in the 1st quarter worth $59,000. Finally, ProShare Advisors LLC purchased a new position in shares of Candel Therapeutics in the 4th quarter worth $59,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.